rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Erez Chimovits

Director

Company insider

Files Form 4 as: Director, Andrx Corp /de/; Director and 10% owner, Braveheart Bio; Director and 10% owner, Upstream Bio; Director and 10% owner, BiomX; Director and 10% owner, Adicet Bio; Director and 10% owner, LogicBio Therapeutics; Director and 10% owner, Eledon Pharmaceuticals.

Every Form 4 they filed

In numbers

Trades disclosed
72
Buys
13
Sells
0
Bought
$101.9M
Sold
$0
Companies
7
Companies where not an officer
7
First trade
18 Oct 2018
Last trade
28 Sep 2026
Last filed
30 Sep 2026

Companies traded

Everywhere else they filed: board seats, 10% stakes, other companies
Andrx Corp /de/Director · last 28 Sep 20261 buy · 0 sells
BRVE Braveheart BioDirector, 10% owner · Biotechnology · last 7 Aug 20261 buy · 0 sells
UPB Upstream BioDirector, 10% owner · Biotechnology · last 9 Jun 20261 buy · 0 sells
BiomXDirector, 10% owner · Biotechnology · last 15 Mar 20247 buys · 0 sells
ACET Adicet BioDirector, 10% owner · Biotechnology · last 12 Feb 20210 buys · 0 sells
LogicBio TherapeuticsDirector, 10% owner · last 1 Oct 20202 buys · 0 sells
ELDN Eledon PharmaceuticalsDirector, 10% owner · Biotechnology · last 14 Jan 20201 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/SEC FORM 4 Code C—7,127,019filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/SEC FORM 4 Code C—1,333,975filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/SEC FORM 4 Code C—513,067filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—7,127,019 at $0.00filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—1,333,975 at $0.00filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—513,067 at $0.00filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code C—256,448 at $0.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/SEC FORM 4 Code C—256,448filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/SEC FORM 4 Bought$1.0M61,516 at $17.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—7,127,019 at $0.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—1,333,975 at $0.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—513,067 at $0.00filing
28 Sep 2026filed 30 Sep 2026Andrx Corp /de/option or derivativeSEC FORM 4 Code C—256,448 at $0.00filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx PharmaceuticalsBiotechnologySEC FORM 4 Code C—7,127,019filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx PharmaceuticalsBiotechnologySEC FORM 4 Code C—1,333,975filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx PharmaceuticalsBiotechnologySEC FORM 4 Code C—513,067filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx PharmaceuticalsBiotechnologySEC FORM 4 Code C—256,448filing
28 Sep 2026filed 30 Sep 2026ADRX ADARx PharmaceuticalsBiotechnologySEC FORM 4 Bought$1.0M61,516 at $17.00filing
7 Aug 2026filed 11 Aug 2026BRVE Braveheart BioBiotechnologySEC FORM 4 Code C—9,132,420filing
7 Aug 2026filed 11 Aug 2026BRVE Braveheart BioBiotechnologySEC FORM 4 Bought$30.0M1,666,667 at $18.00filing

News

ADARx Pharmaceuticals, Inc. (NASDAQ:ADRX) Sees Significant Growth in Short InterestADRX · dailypolitical.com · 15 Oct 2026

0 headlines in the last 90 days name Erez Chimovits; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.

Sectors

Health Care11
Not placed3

Buys in green, sells in red, by the company’s sector.

Related people

Carl L. GordonDirector and 10% owner · Director and 10% owner at ADARx Pharmaceuticals, filing Form 4 there in the last year
ORBIMED ADVISORS LLCDirector and 10% owner · Director and 10% owner at ADARx Pharmaceuticals, filing Form 4 there in the last year
LAV Biosciences Fund V, L.P.10% owner · 10% owner at ADARx Pharmaceuticals, filing Form 4 there in the last year
SR ONE CAPITAL MANAGEMENT, LLC10% owner · 10% owner at ADARx Pharmaceuticals, filing Form 4 there in the last year
Simeon GeorgeDirector · Director and 10% owner at ADARx Pharmaceuticals, filing Form 4 there in the last year
Aaron DeykinChief Medical Officer · Also traded UPB in the last 90 days
Adam HoughtonChief Business Officer · Also traded UPB in the last 90 days
Allison AmbroseGeneral Counsel · Also traded UPB in the last 90 days